MedTrace Logo

ABCSG 8 - Adjuvant Treatment in Patients With Hormone Receptor-positive Breast Cancer With Good to Moderate Differentiation.

NCT00291759 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 3858

Last updated 2013-01-30

No results posted yet for this study

Summary

The purpose of this study is to assess the difference in event-free survival between postmenopausal women with hormone receptor-positive early breast cancer who switched from tamoxifen to anastrozole and those who continued to receive tamoxifen.

Conditions

Interventions

DRUG

Tamoxifen

DRUG

Anastrozole

Sponsors & Collaborators

Principal Investigators

  • Raimund Jakesz, MD · Austrian Breast and Colorectal Cancer Study Group

  • AstraZeneca Austria Medical Director, MD · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1996-01-31
Primary Completion
2009-06-30
Completion
2009-06-30

Countries

  • Austria

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00291759 on ClinicalTrials.gov